Parameters | serious (N = 22) | non-serious (N = 581) | P value |
Gender, n (% male) | 15 (68.2%) | 323 (55.6%) | 0.243 |
Age, year | 70.09 ± 8.59 | 65.59 ± 11.08 | 0.060 |
Smoking, n (%) | 10 (45.4%) | 138 (23.8%) | 0.020 |
Drinking, n (%) | 5 (22.7%) | 57 (9.8%) | 0.049 |
Past history: |
|
|
|
Hypertension, n (%) | 14 (63.6%) | 389 (67.0%) | 0.746 |
Diabetes, n (%) | 8 (36.4%) | 112 (19.3%) | 0.089 |
Hyperlipidemia, n (%) | 1 (4.5%) | 58 (10.0%) | 0.633 |
Stroke, n (%) | 3 (13.6%) | 116 (20.0%) | 0.646 |
Renal insufficiency, n (%) | 0 (0%) | 7 (1.2%) | 1.000 |
Peptic injury, n (%) | 6 (27.3%) | 58 (10.0%) | 0.026 |
Combined medication: |
|
|
|
PPI (%) | 10 (45.5%) | 394 (67.8%) | 0.029 |
Heparin sodium, n (%) | 13 (59.1%) | 237 (40.8%) | 0.087 |
Dabigatran, n (%) | 0 (0%) | 6 (1.0%) | 1.000 |
Warfarin, n (%) | 0 (0%) | 21 (3.6%) | 1.000 |
Ticagrelor, n (%) | 2 (9.1%) | 31 (5.3%) | 0.777 |
β-blocker, n (%) | 14 (63.6%) | 407 (70.1%) | 0.520 |
CCB, n (%) | 11 (50.0%) | 254 (43.7%) | 0.560 |
ACEI, n (%) | 4 (18.2%) | 106 (18.2%) | 1.000 |
ARB, n (%) | 7 (31.8%) | 190 (32.7%) | 0.931 |
Diuretics, n (%) | 2 (9.1%) | 80 (13.8%) | 0.755 |
Antidiabetics, n (%) | 5 (22.7%) | 66 (11.4%) | 0.198 |
Digoxin, n (%) | 0 (0%) | 14 (2.4%) | 1.000 |
Amiodarone, n (%) | 0 (0%) | 14 (2.4%) | 1.000 |